Yeah, we need the next quarterly to shed some light. The R&D...

Yeah, we need the next quarterly to shed some light. The R&D refund will mean there is still cash in the bank, but the amount left is the key. If the next quarterly is a big step towards profitability as they outlined in the investor presentation, then we should see a price spike and a potential cap raising at a higher level.

For reasons outlined in other threads I think the next quarterly should read well. I would be very disappointed if it didn't and would likely sell to be honest. I gave management the benefit of the doubt last quarterly but there can't be any excuses this time. Chinese approval has been in place for the whole quarter, the good news from the Chinese ICU and the pre-eclampsia screening should be filtering through.